Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Health and Quality of Life Outcomes
Published in: Health and Quality of Life Outcomes 1/2016

Open Access 01-12-2016 | Research

Quality of life utility values for hereditary haemochromatosis in Australia

Authors: Barbara de Graaff, Amanda Neil, Kristy Sanderson, Kwang Chien Yee, Andrew J. Palmer

Published in: Health and Quality of Life Outcomes | Issue 1/2016

Login to get access

Abstract

Background

Hereditary hemochromatosis (HH) is a common autosomal recessive disorder amongst persons of northern European heritage. If untreated, iron accumulates in parenchymal tissues causing morbidity and mortality. As diagnosis often follows irreversible organ damage, screening programs have been suggested to increase early diagnosis. A lack of economic evidence has been cited as a barrier to establishing such a program. Previous analyses used poorly estimated utility values. This study sought to measure utilities directly from people with HH in Australia.

Methods

Volunteers with HH were recruited to complete a web-based survey. Utility was assessed using the Assessment of Quality of Life 4D (AQOL-4D) instrument. Severity of HH was graded into four categories. Multivariable regression analysis was performed to identify parameters associated with HSUV.

Results

Between November 2013 and November 2014, 221 people completed the survey. Increasing severity of HH was negatively associated with utility. Mean (standard deviation) utilities were 0.76 (0.21), 0.81 (0.18), 0.60 (0.27), and 0.50 (0.27) for categories 1–4 HH respectively. Lower mean utility was found for symptomatic participants (categories 3 and 4) compared with asymptomatic participants (0.583 v. 0.796). Self-reported HH-related symptoms were negatively associated with HSUV (r = −0.685).

Conclusions

Symptomatic stages of HH and presence of multiple self-reported symptoms were associated with decreasing utility. Previous economic analyses have used higher utilities which likely resulted in underestimates of the cost effectiveness of HH interventions. The utilities reported in this paper are the most robust available, and will contribute to improving the validity of future economic models for HH.
Literature
1.
2.
3.
Feder JN. The hereditary hemochromatosis gene (HFE): a MHC class I-like gene that functions in the regulation of iron homeostasis. Immunol Res. 1999;20(2):175–85.CrossRefPubMed
4.
Altes A et al. Prevalence of the C282Y, H63D, and S65C mutations of the HFE gene in 1,146 newborns from a region of Northern Spain. Genet Test. 2004;8(4):407–10.CrossRefPubMed
5.
Pedersen P, Melsen GV, Milman N. Frequencies of the haemochromatosis gene (HFE) variants C282Y, H63D and S65C in 6,020 ethnic Danish men. Ann Hematol. 2008;87(9):735–40.CrossRefPubMed
6.
Gagne G et al. Hereditary hemochromatosis screening: effect of mutation penetrance and prevalence on cost-effectiveness of testing algorithms. Clin Genet. 2007;71(1):46–58.CrossRefPubMed
7.
Adams PC, Valberg LS. Screening blood donors for hereditary hemochromatosis: decision analysis model comparing genotyping to phenotyping. Am J Gastroenterol. 1999;94(6):1593–600.CrossRefPubMed
8.
Distante S et al. The origin and spread of the HFE-C282Y haemochromatosis mutation. Hum Genet. 2004;115(4):269–79.CrossRefPubMed
9.
Olynyk JK et al. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med. 1999;341(10):718–24.CrossRefPubMed
10.
Allen KJ et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med. 2008;358(3):221–30.CrossRefPubMed
11.
Mclaren CE et al. Prevalence of Heterozygotes for Hemochromatosis in the White-Population of the United-States. Blood. 1995;86(5):2021–7.PubMed
12.
Adams PC et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med. 2005;352(17):1769–78.CrossRefPubMed
13.
Merryweather-Clarke A et al. Geography of HFE C282Y and H63D mutations. Genet Test. 2000;4(3):183–98.CrossRefPubMed
14.
Biotechnology Australia. In: A.G.A.B. Australia, editor. Genetics in Family Medicine: The Australian Handbook for General Practitioners: Hereditary haemochromatosis. Canberra: National Health and Medical Research Council; 2007.
15.
Barton J, Edwards CQ. Hemochromatosis: Genetics, patholphysiology, diagnosis and treatment. U.K: Cambridge University Press; 2000.CrossRef
16.
Adams P, Brissot P, Powell LW. EASL International Consensus Conference on Haemochromatosis. J Hepatol. 2000;33(3):485–504.CrossRefPubMed
17.
Whitlock EP et al. Screening for hereditary hemochromatosis: A systematic review for the US Preventive Services Task Force. Ann Intern Med. 2006;145(3):209–23.CrossRefPubMed
18.
Powell LW et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med. 2006;166(3):294–301.CrossRefPubMed
19.
Asberg A et al. Screening for hemochromatosis: High prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol. 2001;36(10):1108–15.CrossRefPubMed
20.
21.
Ajioka RS, Kushner JP. Clinical consequences of iron overload in hemochromatosis homozygotes. Blood. 2003;101(9):3351–3. discussion 3354–8.CrossRefPubMed
22.
Adams PC et al. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology. 1997;25(1):162–6.CrossRefPubMed
23.
Allen KJ, Warner B, Delatycki MB. Clinical haemochromatosis in HFE mutation carriers. Lancet. 2002;360(9330):412–3. author reply 413–4.CrossRefPubMed
24.
Mundy L, Merlin T. Population genetic screening for haemochromatosis: identifying asymptomatic “at risk” homozygous individuals. Horizon Scanning Prioritising Summary, vol. 1. Adelaide: Adelaide Health Technology Assessment (AHTA); 2003.
25.
Adams P, Brissot P, Powell L. EASL International Consensus Conference on Haemochromatosis - Part II. Expert document. J Hepatol. 2000;33(3):487–96.CrossRef
26.
Allen KJ. Population genetic screening for hereditary haemochromatosis: are we a step closer? Med J Aust. 2008;189(6):300–1.PubMed
27.
Barton JC, Acton RT. Population screening for hemochromatosis: has the time finally come? Curr Gastroenterol Rep. 2000;2(1):18–26.CrossRefPubMed
28.
Gertig DM, Hopper JL, Allen KJ. Population genetic screening for hereditary haemochromatosis. Med J Aust. 2003;179(10):517–8.PubMed
29.
Wilson JM, Jungner YG. Principles and practice of mass screening for disease. Bol Oficina Sanit Panam. 1968;65(4):281–393.PubMed
30.
Nisselle AE et al. Implementation of HaemScreen, a workplace-based genetic screening program for hemochromatosis. Clin Genet. 2004;65(5):358–67.CrossRefPubMed
31.
Grosse SD et al. Population screening for genetic disorders in the 21st century: evidence, economics, and ethics. Public Health Genomics. 2010;13(2):106–15.CrossRefPubMed
32.
Rogowski WH. The Cost-Effectiveness of Screening for Hereditary Hemochromatosis in Germany: A Remodeling Study. Med Decis Making. 2009;29(2):224–38.CrossRefPubMed
33.
de Graaff B, et al. A Systematic review and narrative synthesis of health economic studies conducted for hereditary haemochromatosis. Appl Health Econ Health Policy. 2015;13(5):469–83.CrossRefPubMed
34.
National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal. United Kingdom: NICE; 2013.
35.
Pharmaceutical Benefits Advisory Committee. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee. Canberra: Australian Government Department of Health: 2013.
36.
Richardson J, Hawthore G. Negative Utility Scores and Evaluating the AQoL All Worst Health State. Melbourne: Monash University; 2001.
37.
Patrick DL, et al. Measuring preferences for health states worse than death. Med Decis Making. 1994;14(1):9–18.CrossRefPubMed
38.
Hawthorne G, Richardson J, Osborne R. The Assessment of Quality of Life (AQoL) instrument: a psychometric measure of health-related quality of life. Qual Life Res. 1999;8(3):209–24.CrossRefPubMed
39.
Hawthorne G, Richardson J, Day NA. A comparison of the Assessment of Quality of Life (AQoL) with four other generic utility instruments. Ann Med. 2001;33(5):358–70.CrossRefPubMed
40.
Hawthorne G, Korn S, Richardson J. Population norms for the AQoL derived from the 2007 Australian National Survey of Mental Health and Wellbeing. Aust N Z J Public Health. 2013;37(1):7–16.CrossRefPubMed
41.
42.
Mundy L, Merlin T. In: AHTA, editor. Population genetic screening for haemochromatosis: identifying asymptomatic “at risk” homozygous individuals. Horizon Scanning Prioritising Summary, vol. 1. Adelaide: AGDHA; 2004.
43.
Britt H, Henderson J, Charles J. General practice activity in Australia 2011–12. In: General Practice Series. Sydney: Sydney University Press; 2012.
44.
45.
Cullen W, Kearney Y, Bury G. Prevalence of fatigue in general practice. Ir J Med Sci. 2002;171(1):10–2.CrossRefPubMed
46.
Kenter EG et al. Tiredness in Dutch family practice. Data on patients complaining of and/or diagnosed with “tiredness”. Fam Pract. 2003;20(4):434–40.CrossRefPubMed
47.
48.
Asberg A et al. Benefit of population-based screening for phenotypic hemochromatosis in young men. Scand J Gastroenterol. 2002;37(10):1212–9.CrossRefPubMed
49.
Adams PC, Kertesz AE, Valberg LS. Screening for hemochromatosis in children of homozygotes: prevalence and cost-effectiveness. Hepatology (Baltimore, Md). 1995;22(6):1720–7.
50.
Adams PC, Gregor JC, Kertesz AE, Valberg LS. Screening blood donors for hereditary hemochromatosis: decision analysis model based on a 30-year database. Gastroenterol Clin North Am. 1995;109:177–88.
51.
Fryback DG et al. US norms for six generic health-related quality-of-life indexes from the National Health Measurement study. Med Care. 2007;45(12):1162–70.PubMedCentralCrossRefPubMed
52.
McLernon DJ, Dillon J, Donnan PT. Health-state utilities in liver disease: a systematic review. Med Decis Making. 2008;28(4):582–92.CrossRefPubMed
53.
Lung TW et al. A meta-analysis of health state valuations for people with diabetes: explaining the variation across methods and implications for economic evaluation. Qual Life Res. 2011;20(10):1669–78.CrossRefPubMed
54.
Holland R et al. Patients’ self-assessed functional status in heart failure by New York Heart Association class: a prognostic predictor of hospitalizations, quality of life and death. J Card Fail. 2010;16(2):150–6.PubMedCentralCrossRefPubMed
55.
Sahinbegovic E et al. Musculoskeletal disease burden of hereditary hemochromatosis. Arthritis Rheum. 2010;62(12):3792–8.CrossRefPubMed
56.
Barton JC et al. Initial screening transferrin saturation values, serum ferritin concentrations, and HFE genotypes in whites and blacks in the Hemochromatosis and Iron Overload Screening Study. Genet Test. 2005;9(3):231–41.CrossRefPubMed
57.
McDonnell SM et al. A survey of 2,851 patients with hemochromatosis: Symptoms and response to treatment. Am J Med. 1999;106(6):619–24.CrossRefPubMed
58.
Adams PC, Speechley M. The effect of arthritis on the quality of life in hereditary hemochromatosis. J Rheumatol. 1996;23(4):707–10.PubMed
Metadata
Title
Quality of life utility values for hereditary haemochromatosis in Australia
Authors
Barbara de Graaff
Amanda Neil
Kristy Sanderson
Kwang Chien Yee
Andrew J. Palmer
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2016
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-016-0431-9

Other articles of this Issue 1/2016

Health and Quality of Life Outcomes 1/2016 Go to the issue

Research

Reliability and validity of the Chinese mandarin version of PedsQL™ 3.0 transplant module

Erratum

Erratum to: Metformin improved health-related quality of life in ethnic Chinese women with polycystic ovary syndrome

Research

Psychometric study of the European Portuguese version of the PedsQL 3.0 Cancer Module

Research

Structural equation modeling of the quality of life for patients with marfan syndrome

Research

The impact of health literacy and life style risk factors on health-related quality of life of Australian patients

Research

Victimisation, poly-victimisation and health-related quality of life among high school students in Vietnam: a cross-sectional survey